Elnora AI

Elnora AI, founded in 2021 and based in Amsterdam, offers an AI-driven platform that automates and optimizes the creation of wet-lab protocols for biomedical research. Its core innovation is the systematic learning from all experimental outcomes, including failures, which are typically discarded, to enhance the reliability and efficiency of future protocols. The company targets R&D teams in biotechnology and pharmaceutical companies, integrating via APIs and the Model Context Protocol (MCP) to connect with tools like Benchling and lab informatics systems. As a private, early-stage platform company, Elnora operates in the rapidly growing intersection of AI and life sciences R&D.

An AI agent that generates and optimizes biomedical lab protocols by learning from experimental outcomes (including failures). It uses natural language input, integrates via APIs and the Model Context Protocol (MCP), and connects to lab software like ELNs to fit into existing workflows.

Elnora competes with broad AI drug discovery platforms (e.g., Insilico Medicine, Recursion) that may have wet-lab components, electronic lab notebook (ELN) and lab information management system (LIMS) vendors adding AI features (e.g., Benchling, Dotmatics), and a growing number of startups focused on AI for lab automation and experimental design. Its differentiation lies in its dedicated agent-based approach to protocol generation and its explicit learning-from-failure mechanism.